Adaptimmune rise exceeds 20% on back of new results

16 March 2018

A second set of encouraging results have led Rafael Amado, Adaptimmune’s (Nasdaq: ADAP) chief medical officer, to restate the belief that its T-cell receptor (TCR) therapies will be capable of addressing multiple solid tumors.

The results have also prompted the share price of the UK-headquartered biotech to go up by more than 20% within two days of trading, to $11.09 as Friday's trading entered the final third.

On Thursday, the company reported three partial responses, two confirmed and one to be confirmed, and one stable disease in the first four patients dosed with NY-ESO SPEAR T-cells in a second solid tumor -myxoid/ round cell liposarcoma (MRCLS).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK